argenx SE American Depositary Receipt (ARGX)
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
argenx: Myositis Data Could Add Billions In Value
argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease affecting at least 45,000 people in the U.S. Efgartigimod's FcRn inhibition reduces pathogenic IgG autoantibodies, showing potential across multiple autoimmune diseases.
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for July 31st
ARGX, VZLA, and SBFG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2024.
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
Here is how argenex SE (ARGX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Friday, the FDA approved Argenx SE's ARGX Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.
